FXN and Friedreich ataxia: The examples of NfL, polyQ-ATXN3, and the pons atrophy in SCA3, together with frataxin in Friedreich’s ataxia, illustrate how well-validated biomarkers can effectively bridge mechanistic insight and trial implementation.